Who are Botox Cosmetic™'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): incabotulinumtoxinA, powder BoNT-A (BOTOX/Vistabel), Botox infiltration, NAFT500 (adult), NAFT600 (adult), OnabotulinumtoxinA 100 UNT [Botox].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botox-cosmetic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Botox Cosmetic™ — Competitive Intelligence Brief

Botox Cosmetic™ (Botox Cosmetic™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin type A. Area: Dermatology / Aesthetics.

marketed Botulinum toxin type A SNAP-25 (synaptosome-associated protein of 25 kDa) Dermatology / Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

Botox Cosmetic™ (Botox Cosmetic™) — Carruthers Dermatology Centre. Botox Cosmetic blocks acetylcholine release at the neuromuscular junction, paralyzing facial muscles and reducing the appearance of wrinkles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Botox Cosmetic™ TARGET	Botox Cosmetic™	Carruthers Dermatology Centre	marketed	Botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
incabotulinumtoxinA	incabotulinumtoxinA	Multiple Sclerosis Center of Northeastern New York	marketed	Botulinum toxin type A	SNARE complex (synaptobrevin/VAMP)
powder BoNT-A (BOTOX/Vistabel)	powder BoNT-A (BOTOX/Vistabel)	Galderma R&D	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
NAFT500 (adult)	NAFT500 (adult)	Merz North America, Inc.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
NAFT600 (adult)	NAFT600 (adult)	Merz North America, Inc.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
OnabotulinumtoxinA 100 UNT [Botox]	OnabotulinumtoxinA 100 UNT [Botox]	Women and Infants Hospital of Rhode Island	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin type A class)

Merz North America, Inc. · 2 drugs in this class
Department of Medical Services Ministry of Public Health of Thailand · 2 drugs in this class
Brigitte Schürch · 1 drug in this class
Carruthers Dermatology Centre · 1 drug in this class
Galderma R&D · 1 drug in this class
Huons Co., Ltd. · 1 drug in this class
Innovaderm Research Inc. · 1 drug in this class
Lupo Center for Aesthetic and General Dermatology · 1 drug in this class
Merz Aesthetics GmbH · 1 drug in this class
Multiple Sclerosis Center of Northeastern New York · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botox Cosmetic™ — Competitive Intelligence Brief. https://druglandscape.com/ci/botox-cosmetic. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab